^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    XH001

    i
    Associations

    News

    Trials
    Company:
    NeoCura
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    23d
    XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=24, Recruiting, Wu Wenming | Not yet recruiting --> Recruiting | N=12 --> 24
    Enrollment open • Enrollment change • Checkpoint inhibition
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Yervoy (ipilimumab) • Tyvyt (sintilimab) • capecitabine • XH001
    1year
    XH001 Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=12, Not yet recruiting, Wu Wenming
    New trial
    |
    Yervoy (ipilimumab) • capecitabine • XH001
    almost2years
    A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors (clinicaltrials.gov)
    P=N/A, N=9, Recruiting, jianming xu
    New trial • Metastases
    |
    Tyvyt (sintilimab) • XH001